How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,228 results for

Mean Corpuscular Volume

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model (PubMed)

human β-globin (HBB) resulted in a vector concentration of 0.001-0.6 copies/cell. Most hematological indices were higher in treated than untreated HET mice, including hemoglobin and mean corpuscular volume, but were still lower than in WT. Therefore, direct IUGT and IUHCT strategies can be used to achieve hematological improvement but require further dose optimization. IUHCT will be useful combined with postnatal transplantation to further enhance engraftment.Copyright © 2018 ISEH – Society

Full Text available with Trip Pro

2018 Experimental Hematology

142. Evaluation of Erythroid Disturbance and Thiol-Disulphide Homeostasis in Patients with Psoriasis (PubMed)

Evaluation of Erythroid Disturbance and Thiol-Disulphide Homeostasis in Patients with Psoriasis This study aims to assess how mean corpuscular volume (MCV), red cell distribution width (RDW), and thiol-disulphide homeostasis are altered in psoriasis patients. This is a cross-sectional review of 76 healthy volunteers and 87 psoriasis patients who were consecutively admitted to the department of dermatology. Psoriasis patients and healthy controls were statistically similar with respect to age

Full Text available with Trip Pro

2018 BioMed research international

143. Effects of Consecutive Versus Non-consecutive Days of Resistance Training on Strength, Body Composition, and Red Blood Cells (PubMed)

changes (time × training interaction; p = 0.001). Training increased hematocrit and lowered mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration (p = 0.001-0.041) but did not alter uncorrected RBC, hemoglobin, mean corpuscular volume and RBC distribution width (p = 0.178-0.797). Conclusion: Both C and NC RT induced similar improvements in strength and body composition, and changes in RBC parameters. (...) before RT, and 0 and 24 h post-3rd session in untrained (week 1) and trained (week 12) states. Results: No training × group interaction was found for all strength and body composition parameters (p = 0.075-0.974). Training increased strength for all exercises, bone mineral density, and total body mass via increased lean and bone mass (p < 0.001). There was no interaction (p = 0.076-0.994) and RT induced temporal changes in all RBC parameters (p < 0.001-0.003) except RBC corrected for plasma volume

Full Text available with Trip Pro

2018 Frontiers in physiology

144. Identification of nine novel loci related to hematological traits in a Japanese population (PubMed)

as novel hematological markers: rs4686683 of SENP2 for red blood cell count (FDR = 0.008, P = 5.5 × 10-6); rs3917688 of SELP for mean corpuscular volume (FDR = 0.005, P = 2.4 × 10-6); rs3133745 of C8orf37-AS1 for white blood cell count (FDR = 0.003, P = 1.3 × 10-6); rs13121954 at 4q31.2 for basophil count (FDR = 0.007, P = 3.1 × 10-5); rs7584099 at 2q22.3 (FDR = 2.6 × 10-5, P = 8.8 × 10-8), rs1579219 of HCG17 (FDR = 0.003, P = 2.0 × 10-5), and rs10757049 of DENND4C (FDR = 0.008, P = 5.6 × 10-5

Full Text available with Trip Pro

2018 Physiological genomics

145. Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease (PubMed)

with correction for age, sex and education. In UK Biobank, SNPs with known blood cell measure associations were analysed with Mendelian randomisation to estimate direction of causality. In AddNeuroMed, gene expression data was used in pathway enrichment analysis to identify associations reflecting biological function.Both sample sets evidence a reproducible association between cognitive performance and mean corpuscular haemoglobin (MCH), a measure of average mass of haemoglobin per red blood cell. Furthermore (...) , in the AddNeuroMed cohort, where longitudinal samples were available, we showed a greater decline in red blood cell indices for AD patients when compared to controls (p values between 0.05 and 10-6). In the UK Biobank cohort, we found lower haemoglobin in participants with reduced cognitive function. There was a significant association for MCH and red blood cell distribution width (RDW, a measure of cell volume variability) compared to four cognitive function tests including reaction time and reasoning (p

Full Text available with Trip Pro

2018 Genome medicine

146. A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults

Thromboplastin Time (PTT) below the lower limit of normal (LLN); CK less than 400mg/ml; Glucose, potassium, total protein, and alkaline phosphatase with a toxicity grade of 1 is allowable; albumin above the upper limit of normal (ULN). Laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due to laboratory error may be repeated once. Abnormalities in mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin (...) concentration (MCHC), red cell distribution width (RDW), mean platelet volume (MPV), and nucleated red blood cell count (NRBC CT), which are included in a complete blood count with differential, will not be exclusionary. Has adequate venous access for the infusion. The urine drug screen is negative. Breathalyzer test is negative. Available for follow-up for the duration of the study. Agrees not to participate in vigorous activity 72 hours prior to dosing through day 15 post dosing. Exclusion Criteria

2018 Clinical Trials

147. Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD

through quantitative flow cytometry Mean corpuscular volume [ Time Frame: Change from baseline after supplementation for 8 weeks ] Direct measurement through quantitative flow cytometry Mean corpuscular hemoglobin [ Time Frame: Change from baseline after supplementation for 8 weeks ] Calculated from hemoglobin mass and erythrocyte count Mean corpuscular hemoglobin concentration [ Time Frame: Change from baseline after supplementation for 8 weeks ] Calculated from hemoglobin divided by hematocrit (...) . Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03632876 Recruitment Status : Completed First Posted : August 16, 2018 Last Update Posted : August 16, 2018 Sponsor: Children's Hospital of Philadelphia Collaborators: Penn State

2018 Clinical Trials

148. To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Rela

. The number of subjects with PCI values, will be reported. Number of subjects with abnormal hematology parameters, Part 1 [ Time Frame: up to 4.5 years ] Blood samples will be collected to measure platelets, white blood cell (WBC count), red blood cell (RBC) count, reticulocyte count, hemoglobin, hematocrit, RBC indices, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), basophils, eosinophils, lymphocytes, monocytes and neutrophils. Number (...) Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

149. A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254

, reticulocytes, hemoglobin, hematocrit, RBC indices, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), basophils, eosinophils, lymphocytes, monocytes and neutrophils Number of subjects with clinical chemistry values of PCI [ Time Frame: Up to 25 days ] Blood samples will be collected to measure blood urea nitrogen (BUN), creatinine, fasting glucose, bicarbonate, sodium, potassium, chloride, Total carbon dioxide (CO2), phosphorous, calcium (...) studies before adding more. A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03575962 Recruitment Status : Completed First Posted : July 3, 2018 Last Update Posted : October 15, 2018 Sponsor: ViiV Healthcare

2018 Clinical Trials

150. Vitamin B12 Pregnancy Supplementation

with increased requirements for iron and increased blood volume of up to 40%. Because expansion in plasma volume is higher than the increase in the mass of red blood cells, there is a fall in hemoglobin concentration, which leads to physiological anemia, characterized with lower hemoglobin (Hb), hematocrit and red blood cells, but without changes in mean corpuscular volume (MCV). Anemia in pregnancy is defined with Hb values under 110 g/L in the first trimester and under 105 g/L in the second and third (...) points: on the 8th-10th and 22nd-24th weeks of pregnancy ] RBC count measured in SI (Systeme International) units (Nx10*12/L) Change of Hemoglobin (Hgb) concentration in first and second trimester [ Time Frame: at two time points: on the 8th-10th and 22nd-24th weeks of pregnancy ] Hgb concentration in SI units (g/L) Change of Hematocrit in first and second trimester [ Time Frame: at two time points: on the 8th-10th and 22nd-24th weeks of pregnancy ] volume percentage (%) Change of Mean corpuscular

2018 Clinical Trials

151. First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

. Part A: Number of subjects with abnormal Hematology Values [ Time Frame: Up to 6 weeks ] Number of subjects with abnormal Hematology values including: Platelet Count, red blood cells, white blood cells, Reticulocyte, Hemoglobin, Hematocrit, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, mean corpuscular volume, Mean Corpuscular Hemoglobin, Mean Corpuscular Hemoglobin Concentration, Prothrombin time and Prothrombin time for Part A will be reported. Part B: Number of subjects (...) with abnormal Hematology Values [ Time Frame: Up to 5 weeks ] Number of subjects with abnormal Hematology values including: Platelet Count, red blood cells, white blood cells, Reticulocyte, Hemoglobin, Hematocrit, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, mean corpuscular volume, Mean Corpuscular Hemoglobin, Mean Corpuscular Hemoglobin Concentration, Prothrombin time and Prothrombin time for Part B will be reported. Part C: Number of subjects with abnormal Hematology Values [ Time Frame

2018 Clinical Trials

152. A Study of Acute Myocardial Infarction Using FDY-5301

, Total Protein 2.4 (U/L): Gamma Glutamyl Transferase, ALP, ALT, AST, Lactate Dehydrogenase Thyroid Function Analysis 3.1 Thyroid Stimulating Hormone (mlU/L), Triiodothyronine (ng/dL), Thyroxine (mg/dL) Hematology Analysis 4.1 Activated Clotting Time (seconds), Hemoglobin (g/dL), Red Blood Cell Count (10^6/mcL), Packed Cell Volume (%), Mean Corpuscular Volume (fL), Mean Corpuscular Hemoglobin (fmol/cell), Mean Corpuscular Hemoglobin Concentration (g/dL), Platelet Count (10^9/L), Total and Differential (...) -5301 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03470441 Recruitment Status : Not yet recruiting First Posted : March 20, 2018 Last Update Posted : March 20, 2018 See Sponsor: Faraday Pharmaceuticals, Inc

2018 Clinical Trials

153. The Swedish Spinal Cord Injury Study on Cardiopulmonary and Autonomic Impairment

for trombocytes level Erythrocytes Mean Corpuscular Hemoglobin (Erc-MCH) [ Time Frame: Day 1 ] Analysis of venous blood sample for Erc-MCH level Erythrocytes Mean Corpuscular Volume (Erc-MCV) [ Time Frame: Day 1 ] Analysis of venous blood sample for Erc-MCV level Neutrophils [ Time Frame: Day 1 ] Analysis of venous blood sample for neutrophils level Eosinophils [ Time Frame: Day 1 ] Analysis of venous blood sample for Eosinophils level Basophils [ Time Frame: Day 1 ] Analysis of venous blood sample (...) more. The Swedish Spinal Cord Injury Study on Cardiopulmonary and Autonomic Impairment (SPICA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03515122 Recruitment Status : Enrolling by invitation First Posted : May 3, 2018 Last Update Posted : May 7, 2018 Sponsor: Lund University Collaborator

2018 Clinical Trials

154. Daprodustat Bioequivalence and Food Effect Study

occurrence that at any dose may result in death, is life-threatening, may require hospitalization or prolongation of existing hospitalization, result in persistent disability/incapacity, or may led to any congenital anomaly or birth defect. Number of subjects with abnormal hematology parameters: Part 1 [ Time Frame: Up to Day 16 ] Laboratory assessment for hematology parameters will include Platelet count, haemoglobin (Hgb), Red blood cell (RBC) count, hematocrit, RBC indices like mean corpuscular volume (...) (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and percentage reticulocytes. White blood cell (WBC) count with differential will include neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal hematology parameters: Part 2 [ Time Frame: Up to Day 16 ] Laboratory assessment for hematology parameters will include Platelet count, Hgb, RBC count, hematocrit, RBC indices like MCV, MCH, MCHC, and percentage

2018 Clinical Trials

155. A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement Study in Healthy Volunteers and Subjects With Osteoarthritis (OA)

of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Part A: Number of subjects with abnormal hematology parameters [ Time Frame: Up to 140 days ] Hematology parameters will be assessed including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes; white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement Study in Healthy Volunteers and Subjects With Osteoarthritis (OA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

156. Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model

with hematology parameters of potential clinical concern [ Time Frame: Up to Day 9 ] Blood samples will be collected to measure platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with clinical chemistry parameters of potential clinical concern [ Time Frame: Up to Day 9 ] Blood samples will be collected to measure blood urea (...) signs will be measured in a semi-supine position after 5 minutes rest and will include temperature, systolic and diastolic blood pressure and heart rate. Mean forced expiratory volume in 1 second (FEV1) [ Time Frame: Up to Day 9 ] FEV1 is the volume of air that can be forced out in one second after taking a deep breath. FEV1 was measured by spirometry. Mean forced vital capacity (FVC) [ Time Frame: Up to Day 9 ] FVC is the amount of air which can be forcibly exhaled from the lungs after taking

2018 Clinical Trials

157. Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET

/90Y/111In- DOTATATE/DOTATOC or TAT Known hypersensitivity to 68Gallium, Octreotate, or any of the excipients of 68Ga-DOTATATE, AA infusion or AlphaMedix™. Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to administration of investigational drug. Subjects with unusual hematological parameters, including an increased mean corpuscular volume (MCV) (>100,000), and especially in those who had previous chemotherapy (...) of AlphaMedix™ in Adult Subjects With SSTR (+) NET The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03466216 Recruitment Status : Recruiting First Posted : March 15, 2018 Last Update Posted : March 15, 2018 See Sponsor: Radiomedix

2018 Clinical Trials

158. The Application of Microcurrent in Athletes

-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness Device: Microcurrent Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially (...) with 3 h of sham comparator after training. Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness Device: Microcurrent Microcurrent based

2018 Clinical Trials

159. A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

(total), Creatinine, High sensitivity C-reactive protein (hsCRP) and Total protein in SI units Change in haematology [ Time Frame: Baseline (Day -1), Follow-up (Day 112) ] Parameters: Erythrocytes, Reticulocytes, Thrombocytes, Leucocytes (total), Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Haemoglobin, Haematocrit, Mean corpuscular volume (MCV) and Mean corpuscular haemoglobin concentration (MCHC) in SI units Change in fibrinogen [ Time Frame: Baseline (Day -1), Follow-up (Day 112 (...) number of saved studies (100). Please remove one or more studies before adding more. A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

160. Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

designed to assess subjects impression of disease severity of their anemia of CKD. Absolute values over time for composite of hematology parameters as a measure of safety [ Time Frame: Up to Week 52 ] The following hematology parameters will be measured: Hemoglobin, Hematocrit, RBC count, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), Red cell distribution width (RDW), Reticulocyte count, Platelet count, white blood cell (WBC) count (...) , Total neutrophils, Eosinophils, Monocytes, Basophils, and Lymphocytes Changes from baseline over time in composite of hematology parameters as a measure of safety [ Time Frame: Up to Week 52 ] The following hematology parameters will be measured: Hemoglobin, Hematocrit, RBC count, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), Red cell distribution width (RDW), Reticulocyte count, Platelet count, white blood cell (WBC) count, Total

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>